This company has been marked as potentially delisted and may not be actively trading. Cogent Biosciences (UMRX) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock UMRX vs. ZYME, CALT, ETHZ, SBTX, AVTE, NLTX, BIOA, VIRI, WHWK, and SPRBShould you be buying Cogent Biosciences stock or one of its competitors? The main competitors of Cogent Biosciences include Zymeworks (ZYME), Calliditas Therapeutics AB (publ) (CALT), Flag Ship Acquisition (ETHZ), Silverback Therapeutics (SBTX), Aerovate Therapeutics (AVTE), Neoleukin Therapeutics (NLTX), BioAge Labs (BIOA), Virios Therapeutics (VIRI), Whitehawk Therapeutics (WHWK), and Spruce Biosciences (SPRB). Cogent Biosciences vs. Its Competitors Zymeworks Calliditas Therapeutics AB (publ) Flag Ship Acquisition Silverback Therapeutics Aerovate Therapeutics Neoleukin Therapeutics BioAge Labs Virios Therapeutics Whitehawk Therapeutics Spruce Biosciences Zymeworks (NYSE:ZYME) and Cogent Biosciences (NASDAQ:UMRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends, media sentiment and earnings. Which has more risk & volatility, ZYME or UMRX? Zymeworks has a beta of 1.51, indicating that its stock price is 51% more volatile than the S&P 500. Comparatively, Cogent Biosciences has a beta of 3.93, indicating that its stock price is 293% more volatile than the S&P 500. Do analysts recommend ZYME or UMRX? Zymeworks presently has a consensus price target of $24.75, suggesting a potential upside of 34.51%. Given Zymeworks' stronger consensus rating and higher probable upside, research analysts plainly believe Zymeworks is more favorable than Cogent Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zymeworks 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.00Cogent Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is ZYME or UMRX more profitable? Cogent Biosciences has a net margin of -96.84% compared to Zymeworks' net margin of -182.75%. Zymeworks' return on equity of -23.00% beat Cogent Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Zymeworks-182.75% -23.00% -18.04% Cogent Biosciences -96.84%-87.78%-52.14% Does the media prefer ZYME or UMRX? In the previous week, Zymeworks had 19 more articles in the media than Cogent Biosciences. MarketBeat recorded 19 mentions for Zymeworks and 0 mentions for Cogent Biosciences. Zymeworks' average media sentiment score of 0.84 beat Cogent Biosciences' score of 0.00 indicating that Zymeworks is being referred to more favorably in the media. Company Overall Sentiment Zymeworks Positive Cogent Biosciences Neutral Do insiders and institutionals hold more shares of ZYME or UMRX? 92.9% of Zymeworks shares are owned by institutional investors. Comparatively, 26.4% of Cogent Biosciences shares are owned by institutional investors. 1.9% of Zymeworks shares are owned by insiders. Comparatively, 31.5% of Cogent Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has preferable valuation & earnings, ZYME or UMRX? Cogent Biosciences has lower revenue, but higher earnings than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZymeworks$122.87M11.26-$118.67M-$0.97-18.97Cogent Biosciences$22.50M30.94-$31.83M-$1.04-15.76 SummaryZymeworks beats Cogent Biosciences on 12 of the 17 factors compared between the two stocks. Get Cogent Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for UMRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding UMRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart UMRX vs. The Competition Export to ExcelMetricCogent BiosciencesPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$696.07M$1.01B$6.10B$10.50BDividend YieldN/A4.84%5.73%4.81%P/E Ratio-21.571.2584.5227.09Price / Sales30.9429.97611.79219.27Price / CashN/A17.6337.1661.22Price / Book15.768.0312.246.52Net Income-$31.83M-$7.71M$3.32B$276.75M Cogent Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)UMRXCogent BiosciencesN/A$16.39+0.2%N/A+44.1%$696.07M$22.50M-21.5772ZYMEZymeworks2.7489 of 5 stars$16.68+1.1%$21.43+28.5%+36.6%$1.25B$122.87M-11.12460Trending NewsAnalyst ForecastAnalyst RevisionCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180ETHZFlag Ship AcquisitionN/A$2.32-0.4%N/AN/A$383.12MN/A-0.157News CoverageStock SplitGap DownSBTXSilverback TherapeuticsN/A$10.33+0.6%N/A-38.8%$372.48MN/A-4.2783High Trading VolumeAVTEAerovate TherapeuticsN/A$9.04-1.1%N/A-87.9%$262.02MN/A-3.0220High Trading VolumeNLTXNeoleukin TherapeuticsN/A$23.47+1.6%N/A-35.8%$220.57MN/A-7.5590News CoverageHigh Trading VolumeBIOABioAge LabsN/A$5.67+1.3%N/AN/A$200.76MN/A0.00N/AVIRIVirios TherapeuticsN/A$6.76+1.0%$5.00-26.0%+35.7%$130.18MN/A-25.045WHWKWhitehawk Therapeutics1.598 of 5 stars$2.13-4.1%N/AN/A$104.62M$25.98M-35.5021News CoverageGap DownSPRBSpruce Biosciences0.8126 of 5 stars$160.07-12.3%$131.25-18.0%+312.6%$102.56M$4.91M-1.8620Analyst Forecast Related Companies and Tools Related Companies ZYME Alternatives CALT Alternatives ETHZ Alternatives SBTX Alternatives AVTE Alternatives NLTX Alternatives BIOA Alternatives VIRI Alternatives WHWK Alternatives SPRB Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:UMRX) was last updated on 10/18/2025 by MarketBeat.com Staff From Our PartnersBuy alert: Move $1,000 before Tesla’s Optimus launchElon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredThe Truth about AI Stocks’ Money MachineBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredNext opportunity for crypto millionsThe floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cogent Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cogent Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free UMRX Stock Alerts